SCHEMBL5156677

SCHEMBL5156677

COC(=O)c1ccc(OC[C@@H]2C[C@H](NS(C)(=O)=O)CN2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.38
MMP1 P03956 2/20 0.38
MMP2 P08253 2/20 0.38
MMP3 P08254 2/20 0.38
MMP7 P09237 2/20 0.38
MMP13 P45452 2/20 0.38
HCRTR2 O43614 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPK1 P28482 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NR1H2 P55055 1/20 0.37
GPR119 Q8TDV5 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152402 0.84 POLB (0.46) NR1H2
SCHEMBL5155194 0.84 CYP1A2 (0.44) MAPTKDM4EMEN1ALDH1A1HTT
SCHEMBL5149679 0.84 MAPT (0.43) MAPTKDM4EMEN1ALDH1A1HTT
SCHEMBL6543115 0.84 CYP1A2 (0.44) MAPTKDM4EMEN1ALDH1A1HTT
SCHEMBL5153275 0.84 MAPT (0.38) MAPTALDH1A1MAPK1SMN1; SMN2HDAC1
SCHEMBL5150122 0.83 MAPT (0.42) MAPTKDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL5151613 0.83 MAPT (0.42) MAPTKDM4EMEN1ALDH1A1HTT
SCHEMBL6966611 0.83 MAPT (0.42) MAPTKDM4EMEN1ALDH1A1HTT
SCHEMBL5186551 0.82 HTR4 (0.39)
SCHEMBL5153035 0.81 MAPT (0.40) MAPTKDM4EMEN1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 MAPT 3229/4885MMP1 1626/4885MMP2 701/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 MAPT 3296/4885MMP1 2159/4885MMP2 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.